Search for a trial

Assessment of the prognostic value of MM related bone disease as detected by Whole Body X Ray (WBXR), Whole Body - Magnetic Resonance Imaging (WB-MRI) and FluoroDeoxyGlucose - Positron Emission Tomography - Computer Tomography (FDG-PET-CT) at diagnosis (part I) and in follow-up (part II)

Primary objective: To assess the prognostic value of MM related bone disease as detected by WBXR, WB-MRI and FDG-PET-CT in terms of progression free survival. To determine the conversion rate, defined as complete normalization, of FDG-PET-CT, after…

Evaluation of bone marrow hypoxia with 18F-FAZA PET in patients with relapsing multiple myeloma; a pilot study

This pilot study will evaluate whether tumour hypoxia can be demonstrated in the bone marrow compartment of relapsing MM patients by using the tracer 18F-FAZA. The results will be compared with the results of the FDG-PET scan. In addition in vitro…

Evaluation of VEGF expression with 89Zr-bevacizumab PET scan in patients with relapsing multiple myeloma; a feasibility study.

In the present study we will perform a feasibility study to demonstrate that 89Zirconium-bevacizumab PET scanning can visualize multiple myeloma lesions. Data from the present study may be used to design further studies with regard to the expression…

Somatostatin receptor scintigraphy in patients with multiple myeloma or plasmocytoma

Objective of the studyThe present pilot study will be focused to define the sensitivity of SRS in MM patients and in patients with plasmacytoma. This in comparison to X-ray examination. In addition it will be investigated whether SRS can be used as…

Effects of bortezomib on bone turnover during treatment of relapsed multiple myeloma: a pilot study of quantitative in-vivo monitoring.

1. The accurateness of the imaging techniques will be evaluated for quantitatively measuring in-vivo and on-site bone turnover in this specific category of patients, i.e. patients with myeloma bone disease.Bone turnover will be measured using * in…

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (>= 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT).

Primary Objective:Efficacy:· Evaluate the efficacy of subcutaneous (sc) azacitidine in combination with durvalumab as compared with subcutaneous azacitidine alone in the defined study population.Secondary Objectives:Safety:· Assess the safety and…